New Promises for Hepatitis C Cure in HIV Coinfection
New Promises for Hepatitis C Cure in HIV Coinfection
Pablo Labarga
NULL
*Correspondence: Pablo Labarga, Email not available
Abstract
One of the most eagerly awaited news of 2013 was the approval in December of another two direct-acting antivirals for hepatitis C, Janssen’s HCV protease inhibitor simeprevir (Olysio®) and Gilead’s HCV polymerase inhibitor sofosbuvir (Sovaldi®). Sofosbuvir plus ribavirin is the first interferon-free combination approved for patients infected with HCV genotypes 2 or 3 and those with HCV genotype 1 who cannot tolerate the side effects of interferon.
